[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532173":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":52,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ammonium chloride","ACTIVE_COMPARATOR","Participants will be randomized to ammonium chloride vs placebo. On Day 0 and 1, the participant will take ammonium chloride or placebo 75 mmol twice daily.\n\nOn Day 2, the participant will take ammonium chloride 150 mmol or placebo once",[13],"Drug: Ammonium Chloride",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ammonium Chloride","Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.",[9],null,{"type":21,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"affiliation":5,"role":31},"Jeffrey Testani, MD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":25,"email":37},"Veena Rao, PHD","CONTACT","2037373571","veena.s.rao@yale.edu",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":25},"RECRUITING","New Haven","Connecticut","06510","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-72.92816,41.30815,{"lat":50,"lon":49},{"type":31,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Jeffrey Testani","Associate Professor of Medicine",[56],{"name":57,"class":58},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100532173","phase-1-mechanisms-of-diuretic-resistance-in-heart-failure-aim-3-100532173",false,"NCT06209359","Mechanisms of Diuretic Resistance in Heart Failure, Aim 3","MsDR Aim 3","Inclusion Criteria:\n\n* Clinical diagnosis of heart failure\n* No plan for titration\u002Fchange of heart failure medical or device therapies during the study period.\n* Absence of non-elective hospitalizations in the previous 2 months.\n* At optimal volume status by symptoms, exam, and dry weight.\n* Serum potassium ≤ 5.0 mmol\u002FL\n* Serum sodium ≥ 130 milliequivalents\u002F liter (mEq\u002FL)\n* Hemoglobin ≥8 g\u002FdL\n* Age \\>18 years\n* Objective evidence of diuretic resistance to a 10mg bumetanide challenge (screening visit may occur under this protocol or HIC2000032328 or HIC2000034315) defined as:\n\n  * FENa \\\u003C10% and total sodium output \\\u003C150mmol\n  * And at least one of the following criteria:\n\n    * Chronic home furosemide dose greater than or equal to 80mg furosemide equivalents\n    * eGFR \\\u003C 60ml\u002Fmin\n    * Serum chloride \\\u003C100mmol\u002FL\n    * FENa \\\u003C5% and total sodium output \\\u003C75mmol on the 2 hour\n\nExclusion Criteria:\n\n* Glomerular filtration rate (GFR) \\\u003C20 ml\u002Fmin\u002F1.73m2\n* Use of any non-loop type diuretic in the last 7 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone ≤50 mg)\n* History of flash pulmonary edema or a \"brittle\" volume sensitive HF phenotype such as amyloid cardiomyopathy\n* Hemoglobin \\\u003C 8 g\u002FdL\n* Pregnant or breastfeeding\n* Cirrhosis or known liver disease\n* History of metabolic or respiratory acidosis within 30 days\n* Use of metformin, acetazolamide, or any other agent that could predispose to acidosis\n* Patients who are on metformin may be enrolled if their metformin can be safely discontinued for the randomized treatment periods in each arm. Any participants who have consistently elevated blood glucose readings \\> 200 mg\u002FdL while inpatient will not be enrolled.\n* Serum bicarbonate level \\\u003C24mmol\u002FL at screening visit\n* Venous potential of hydrogen(pH) \\\u003C7.35 at screening visit\n* Inability to give written informed consent or comply with study protocol or follow-up visits\n* On Lithium therapy\n* On pimozide or thioridazine\n* Diagnosis of liver failure\n* Contraindications or allergy to sulfonamides\n* Any contraindication to thiazide diuretic or allergy to thiazide or bendroflumethiazide","ALL","18 Years",{"count":69,"type":70},50,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","Randomized double-blind placebo-controlled crossover study design",[76,77],"Heart Failure","Diuretic Resistance",[79,80,77],"Diuretic","Cardiomyopathy","2026-05-18",{"date":83,"type":84},"2026-05-22","ACTUAL",{"date":86,"type":84},"2024-07-24",{"date":88,"type":70},"2029-03-01",{"name":5,"class":6},1]